cinacalcet (sensipar) Report issue

Small molecule Orphan Drug FDA Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Cinacalcet is a positive allosteric modulator of calcium sensing receptor. The drug is approved by FDA (Sensipar trade name) and used for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis; hypercalcemia in adult patients with parathyroid carcinoma; hypercalcemia in adult patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy.   NCATS

Chemistry

  • SMILES: C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c2cccc3ccccc23
  • InChIKey: VDHAWDNDOKGFTD-MRXNPFEDSA-N
  • Mol. Mass: 357.42
  • ALogP: 6.14
  • ChEMBL Molecules:
    cinacalcet  
    cinacalcet hydrochloride  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$1.2828 - $3.8488

United States

$3.6673 - $52.6990
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

amg 073 | amg-073 | amg-073 hcl | cinacalcet | cinacalcet hcl | cinacalcet hydrochloride | cnc | krn1493 | mimpara | n-((1r)-1-(naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine | (r)-alpha-methyl-n-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine | regpara | sensipar

Organizations (72)

Research & Development (56)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (17)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (25)

Approved Indications (2)


 

Hypercalcemia (approved 2004)

Hyperparathyroidism, Secondary (approved 2004)

Experimental Indications - Clinical Trial Phases 1-4 (25)


 

Anemia (Phase 4)

Cardiovascular Diseases (Phase 4)

Chronic Kidney Disease-Mineral and Bone Disorder (Phase 3)

Familial Hypophosphatemic Rickets (Phase 1)

Healthy Volunteers (Phase 1)

Hormones (Phase 4)

Hypercalcemia (Phase 3)

Hyperparathyroidism (Phase 4)

Hyperparathyroidism, Primary (Phase 4)

Hyperparathyroidism, Secondary (Phase 4)

Hyperplasia (Phase 3)

Hypophosphatemia (Phase 3)

Kidney Diseases (Phase 4)

Kidney Failure, Chronic (Phase 4)

Kidney Transplantation (Phase 3)

Memory Disorders (Phase 2)

Metabolism (Phase 3)

Nephrology (Phase 4)

Osteoporosis (Phase 4)

Parathyroid Neoplasms (Phase 4)

Prostatic Neoplasms (Phase 2)

Renal Dialysis (Phase 4)

Renal Insufficiency, Chronic (Phase 4)

Vascular Calcification (Phase 4)

Vascular Stiffness (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 72
  • # of Trial Organizations: 56

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue